Spain Brazil Russia France Germany China Korea Japan

Artificial Intelligence driven Marketing Communications

Oct 1, 2020 12:25 PM ET

Global Antibody-Drug Conjugates Market Set for Rapid Growth, to reach Value around USD 2863.49 Million by 2025

iCrowd Newswire - Oct 1, 2020

Zion Market Research has published a new report titled “Antibody-Drug Conjugates Market by Type (Drugs [Kuvan, and Biopten], and Dietary Supplements), by Route of Administration (Oral and Parenteral), and by End User (Hospital Pharmacies, Drug Stores, Online Pharmacies, Pediatric Clinics, and Others): Global Industry Perspective, Comprehensive Analysis and Forecast, 2019 – 2025”.

According to the report, global demand for Antibody-drug conjugate Market was valued at approximately USD 1754.57 Million in 2018, and is expected to generate revenue of around USD 2863.49 Million by end of 2025, growing at a CAGR of around 7.25 % between 2018 and 2025.

Global Antibody-Drug Conjugates Market

Antibody-drug conjugate is one of the class of biopharmaceutical drugs identified as a cancer therapy that has been regulated. In comparison to chemotherapy, antibody-drug conjugates are intended to target and kill tumor cells while protecting healthy cells. Through 2019, more than 56 pharmaceutical companies had produced antibody-drug conjugates. Antibody-drug conjugates are compound molecules composed of an antibody paired with a cytotoxic (anticancer) agent that is biologically active. Antibody-drug conjugates are examples of bioconjugates and immunoconjugates. Antibody-drug conjugates combine the ability of monoclonal antibodies to target with the ability of cytotoxic drugs to destroy cancer. These may be designed to differentiate between healthy and diseased tissue.

Request For Free Sample Report @ 

The growing acceptance and therapeutic potential of ADCs may also be correlated with an exponential increase in the number of patents submitted / granted; the total number of patents grew from 1,395 in 2009 to around 16,500 in the first half of 2019. In the first half of 2019, it rose from 1,395 during 2009 to around 16,500. With more than 200 ADCs being produced in clinical / preclinical stages, the industry is gradually moving from depending on traditional technologies to modern and more reliable methods to conjugate these complex biomolecules. With more than 200 ADCs being produced in clinical / preclinical stages, the industry is gradually moving from depending on traditional technologies to modern and more reliable methods to conjugate these complex biomolecules. Over the years, a variety of well-funded start-ups / small businesses have been developed, offering new techniques of conjugation, more powerful warheads and advanced connecting technologies. In addition, several licensing agreements / collaborations have been inked over the past few years between drug developers and software providers to advance the creation of candidates for ADC pipeline.

The market for Antibody-Drug Conjugates is segmented based on application, technology and region. Based on application, the market is segmented into blood cancer, breast cancer, ovarian cancer, lung cancer, and brain tumor.

Due to factors such as high incidence of global breast cancer and commercial availability of Kadcyla in most major regions, breast cancer was the largest segment generating revenue in 2018. The increasing prevalence of cancer is one of the main drivers of the antibody drug conjugates market. According to the World Health Organization (WHO), breast cancer with 2.09 million cases, 2.09 million cases of lung cancer, 1.80 million cases of colorectal cancer, 1.28 million cases of prostate cancer, 1.04 million cases of skin cancer and 1.03 million cases of stomach cancer are the most popular diagnoses for cancer in 2018.

Based on the Technology segment, the market is separated into cleavable and non-cleavable linkers. It was projected that cleavable linkers would see the fastest growth over the forecast period due to factors such as large use of these linkers and total number of products in the pipeline. In addition, in 2017, two new Pfizer–Besponsa and Mylotarg products were approved for use in developed regions and both feature cleavable connectors.

Regional segmentation includes the current and forecast demand for Asia Pacific, North America, Latin America, Europe, and Middle East & Africa with its further bifurcation into major countries. North America, led by Europe, was the largest manufacturing nation in 2017. Major market players such as Seattle Genetics, Roche, Pfizer, and AbbVie are the main factor contributing to their continued dominance. North America, coupled with well-established health care infrastructure and patient experience, is the most well-established market for using ADCs. As most of the ADCs currently being produced in the U.S. pipeline, it is expected that North America will see the fastest growth over the forecast period. The United States at times. Food and Drug Administration (FDA) is one of the first governing bodies to allow ADC in the United States. Thus, these factors are expected to drive market growth in the region over the forecast period.

Some of the players included in Antibody-Drug Conjugates market are AbbVie Inc., Agensys, Inc., Celldex Therapeutics Inc., Concortis Biotherapeutics, F. Hoffmann-La Roche Ltd., Pfizer Inc., Sanofi S.A., Seattle Genetics, Inc., Synthon Holding B.V., Takeda Pharmaceutical Company Limited amongst others.

The report segments global Antibody-Drug Conjugates market as follows:

Global Antibody-Drug Conjugates MarketApplication Segment Analysis

  • Blood Cancer
    • Leukemia
    • Lymphoma
  • Breast Cancer
  • Ovarian Cancer
  • Lung Cancer
  • Brain Tumor

Global Antibody-Drug Conjugates MarketTechnology Segment Analysis

  • Cleavable Linker
  • Non-cleavable Linker

Global Antibody-Drug Conjugates MarketRegional Segment Analysis

  • North America
    • U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • Middle East and Africa

Inquire more before buying this report @ 

Contact Information:

Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651

Keywords:    Antibody-Drug Conjugates Market

Tags:    IPS, Reportedtimes, iCN Internal Distribution, Research Newswire, English